Why Arcturus Therapeutics Is Trading Higher Today

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Monday after the company announced the completion of the first three dose escalation cohorts in Phase 1 study of its ARCT-810 for Ornithine Transcarbamylase Deficiency.

Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.

Arcturus Therapeutics shares traded up 13.03% to $48.36 on Monday. The stock has a 52-week high of $66.24 and a 52-week low of $8.51.